A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their perceptions about the causes of obesity and treatment goals.

Multinational pharmaceutical firms have been queuing up to announce multi-billion-dollar investments in US facilities. Roche, ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Cheryl Dunye Outfit Jingletown Heads To Cannes Market With Lilly Wachowski, Lawrence Mattis, Killer Films Projects.

The new facility, based in Holly Springs, North Carolina, will support Roche and its unit Genentech's future portfolio of ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...

Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...